Phase 2 N=12 Treatment

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Lymphoma, Non-Hodgkin

Bottom Line

View on ClinicalTrials.gov: NCT00426855 ↗

Enrolled (actual)

Serious AEs

8.3%

Results posted

Apr 2015

Primary outcome: Primary: Optimal Bendamustine Dosage for Further Studies — 60 mg/m^2

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Bendamustine (Drug); Bortezomib (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Peter Moosmann
Primary completion: Feb 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Optimal Bendamustine Dosage for Further Studies	60	—

Summary

The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.

Eligibility Criteria

Inclusion Criteria

Symptomatic recurrent or refractory indolent NHL or B-CLL
Adequate organ and bone marrow function
Karnofsky greater than 50%

Exclusion Criteria

Candidates for autologous stem cell transplantation
Secondary high grade lymphoma
Concurrent severe medical condition

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00426855). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.